Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gene therapy vectors with minor modifications may not require new IND -- FDA addendum to PTC.

Executive Summary

GENE THERAPY VECTORS WITH MINOR MODIFICATIONS MAY NOT REQUIRE NEW IND, an FDA draft "Addendum to The Points to Consider in Human Somatic Cell and Gene Therapy" states. The draft addendum to the 1991 points to consider document, which provides more details than the earlier points to consider, especially with regard to in vivo gene therapies, will be discussed at a Feb. 28-29 meeting of FDA's Biologic Response Modifiers Advisory Committee ("The Pink Sheet" Feb. 5, In Brief). Comments are due March 28.
UsernamePublicRestriction

Register

PS027666

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel